Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Esperion’s phase 3 LDL study raises flags with treatment-arm deaths

fiercebiotechMay 03, 2018

Tag: Esperion , LDL , bempedoic

PharmaSources Customer Service